Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea flag South Korea · Delayed Price · Currency is KRW
998.00
-2.00 (-0.20%)
Sep 22, 2026, 3:30 PM KST

Xcell Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
17,26028,72644,384---
Market Cap Growth
-51.82%-35.28%----
Enterprise Value
18,41533,87338,298---
Last Close Price
998.001661.003373.54---

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.9614.7422.95---
PB Ratio
3.994.024.87---
P/TBV Ratio
4.704.465.17---

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
4.2317.3819.80---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
1.240.770.632.730.690.38
Net Debt / Equity Ratio
0.27-0.20-0.342.160.03-0.52
Net Debt / EBITDA Ratio
-0.120.160.40-0.70-0.041.80
Net Debt / FCF Ratio
-0.110.140.42-0.73-0.031.42
Asset Turnover
0.350.120.140.090.050.10
Inventory Turnover
6.253.874.444.014.673.87
Quick Ratio
0.911.361.900.361.192.83
Current Ratio
1.281.812.140.521.392.93
Return on Equity (ROE)
-271.41%-134.41%-165.90%-170.80%-67.53%-102.65%
Return on Assets (ROA)
-57.12%-41.59%-42.63%-43.01%-26.46%-18.88%
Return on Capital Employed (ROCE)
-151.30%-104.40%-77.90%-177.90%-80.40%-30.90%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-65.85%-38.04%-21.50%---
FCF Yield
-62.19%-36.09%-16.63%---
Buyback Yield / Dilution
-36.11%-16.45%-13.14%-1.02%-5.71%-364.87%